CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 506 enrolled
Drug / intervention
insulin degludec/liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02420262
NCT02420262Phase 3Completed
CompareCT.gov

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/S·interventional·Posted Apr 17, 2015·Updated Mar 29, 2018

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide, insulin glargine, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 506 participants across 117 sites in 12 countries.

Detailed Summary

This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Czechia, France, Greece, Hungary, Israel, Mexico, Russia, Slovakia, Spain, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 17, 2015
Enrollment StartJul 26, 2015
Primary CompletionOct 5, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.2 years ago

Interventions

insulin degludec/liraglutidedrug

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

insulin glarginedrug

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

insulin aspartdrug

Injected s.c./subcutaneously (under the skin) before each main meal.